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To the Editor: Clostridium diffi-
cile is the most common cause of bac-
terial diarrhea in hospitalized patients
(1). Antimicrobial drug therapy is the
most important risk factor associated
with the acquistion of C. difficile, and
several antimicrobial agents including
clindamycin, amoxicillin, and cepha-
lo-sporins have been particularly
associated with C. difficile infection
(2). Acquisition of resistance to clin-
damycin is considered 1 mechanism
whereby clonal strains emerge and
predominate in healthcare environ-
ments (3). Historically, fluoro-
quinolone antimicrobial agents were
considered low risk for C. difficile–
associated-disease; however, recent
studies indicate a shift in the risk asso-
ciated with their use (4). Furthermore,
recent outbreaks in Canada and the
United States have been associated
with fluoroquinolone exposure (4).
Recently, several C. difficile out-
breaks due to PCR ribotype 027
(PCR-027) and associated with
increased disease severity and death
have been reported worldwide (4).
This strain type contains the genes for
binary toxin and has an 18-bp deletion
and a frameshift mutation in tcdC
hypothesized to result in deregulated
expression of toxins A and B. These
strains produce 16× more toxin A and
23× more toxin B in vitro than toxino-
type 0 strains (5). These isolates
demonstrate universal high-level
resistance to fluoroquinolones in con-
trast to that of PCR 027 isolates col-
lected before 2001 (4).
We report the mechanism of fluo-
roquinolone resistance in a cluster (n =
5) of Irish PCR-027 C. difficile iso-
lates that were characterized by using
toxinotyping and 16–23S ribotyping.
Amplification with PCR and sequenc-
ing was used to identify the binary
toxin gene (cdtB) and an 18-bp dele-
tion and a frameshift mutation at posi-
tion 117 in the tcdC gene. Anti-
microbial susceptibility to 5 fluoro-
quinolone antimicrobial drugs was
determined with E-tests (AB-Biodisk,
Solna, Sweden). The quinolone-resist-
ance–determining region (QRDR) of
gyrA and gyrB was amplified by PCR
and characterized. The nucleotide
sequence data for partial sequences of
the  gyrA gene were submitted to
GenBank and assigned accession nos.
DQ821481, DQ821482, DQ821483,
and DQ821484.
PCR ribotyping profiles identified
1 cluster of C. difficile PCR-027 with
clinical isolates that showed indistin-
guishable profiles to the control 027
strain. PCR identified the cdtB, an 18-
bp deletion, and a frameshift mutation
at position 117 in the tcdC gene in all
5 isolates. These strains were univer-
sally resistant to the fluoroquinolones
tested (ofloxacin, ciprofloxacin, levo-
floxacin, moxifloxacin, and gatiflo-
xacin, respectively, MIC >32 µg/mL
[Table]). Control isolates were suscep-
tible to moxifloxacin and gatifloxacin
(MICs 0.3, 0.2 µg/mL, respectively);
however, these strains had reduced
susceptibility to levofloxacin (MIC
3 µg/mL) and were resistant to cipro-
floxacin and oflo-xacin (Table).
Sequence analysis determined that all
5 PCR-027 isolates had a single transi-
tion mutation (C to T), resulting in the
amino acid substitution Thr-82-Ile in
gyrA (Table). No amino acid substitu-
tions were found in the QRDR of gyrB
(data not shown).
Mutations in the active site or the
QRDR of DNA gyrase and topoiso-
merase IV have been associated with
increased resistance to fluoro-
quinolones in several bacteria (6). This
report identifies for the first time a
mutation in gyrA that is associated
with high-level resistance to fluoro-
quinolones in C. difficile PCR-027. In
Escherichia coli, amino acid substitu-
tions that occur at Ser-83 in gyrA have
been associated with fluoroquinolone
resistance (6). Thr-82 in C. difficile
corresponds to Ser-83 in E. coli. Thr-
to-Ile amino acid substitutions corre-
sponding to Ser-83 have been associ-
ated with fluoroquinolone resistance
in several bacteria, including
Pseudomonas aeruginosa,  Entero-
bacter aerogenes,  Campylobacter
jejuni, and C. difficile (6). Ackermann
et al. described 2 mutations in gyrA
that resulted in an amino acid substitu-
tion corresponding to codon 83 in E.
coli. Thirteen of the 18 C. difficile iso-
lates had the Thr-82-Ile substitution,
and 1 strain had a Thr-82-Val substitu-
tion (7). Dridi et al. described this Thr-
82-Ile GyrA substitution in 6 resistant
C. difficile strains corresponding to 3
serogroups, H1, A9, and 1C (8).
Early studies investigating fluo-
roquinolone antimicrobial agents
suggested that most C. difficile iso-
lates were susceptible to these drugs.LETTERS
Antimicrobial drug resistance to this
class has increased with fluoro-
quinolone use, and currently these
drugs remain the most frequently pre-
scribed antimicrobial agents in the
United States and Europe. Acquired
resistance to the newer fluoro-
quinolone antimicrobial agents is not
restricted to ribotype PCR-027,
although different amino acid substi-
tutions in the QRDR of gyrA and
gyrB have been described (7–9).
Wilcox et al. have described high-
level fluoroquinolone resistance in
PCR ribotype-001, an endemic strain
type found in several healthcare set-
tings in the United Kingdom (10). We
have previously described the emer-
gence of a fluoroquinolone-resistant
toxin A–, toxin B–positive strain in
Dublin (9).
We report a mutation in gyrA
associated with fluoroquinolone
resistance in C. difficile PCR-027.
Antimicrobial drug resistance in C.
difficile isolates must be monitored
because the emergence of universal
fluoroquinolone resistance in differ-
ent C. difficile strain types may be a
factor promoting outbreaks in hospi-
tals. As exposure to several different
fluoroquinolone antimicrobial drugs
have been independently associated
with  C. difficile–associated-disease,
restricted use of all fluoroquinolones,
rather than changing from 1
quinolone to another, may be a neces-
sary step toward preventing and con-
trolling C. difficile outbreaks.
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